Genome Editing and Gene Modulation | NMI TT Pharmaservices

home contact company.overview news sitemap print

Custom Cell Services

Contact

NMI-TT Contact Person

Dr. Richard Griesbach

+49 7121 51530 74




Genome Editing and Gene Modulation

Genome Editing by CRISPR/Cas9
Based on our long-standing expertise in generating customised cell lines, we are now also employing the CRISPR/Cas9 genome editing approach. FTO is ensured through a set of license agreements.

    Our offerings:
  • Introduction of specifically site-directed double stand breaks applying the CRISPR/Cas9 technology
  • Generation of target-defective cell lines
  • Larger deletions by two double strand breaks
  • Insertion of specific mutations or extensions into the DNA locus with ectopic repair templates



Gene Modulation by shRNAs and siRNAs

We employ inter alia lentiviral vectors to down-regulate the gene expression of target genes via shRNA-mediated RNA interference (RNAi). Alternatively, we use commercial siRNAs for cell-based RNAi experiments.

    Our offerings:
  • Generation of lentivirus encoding target-specific shRNAs
  • Production of stable knock-down cell lines
  • Validation of target silencing by RT-qPCR, Western blot and/or immunofluorescence microscopy
  • RNAi studies with shRNAs or siRNAs, using a wide range of reader-based and fixed endpoint or live microscopy assays

 

Linked in profile

NMI TT is a subsidiary of NMI